<DOC>
	<DOC>NCT02259127</DOC>
	<brief_summary>A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.</brief_summary>
	<brief_title>A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>ALL PATIENTS: Children &lt;18 years with confirmed HIV1 infection and DTG dose known for the child's age/weightband Parents/carers and children, where applicable, give informed written consent Girls aged 12 years or older who have reached menses must have a negative pregnancy test at screening and be willing to adhere to effective methods of contraception if sexually active Children with coinfections who need to start ART can be enrolled into ODYSSEY according to local/national guidelines Parents/carers and children, where applicable, willing to adhere to a minimum of 96 weeks' followup Recruitment will start from children aged ≥6 and&lt;18 years for whom dosing information and formulations are currently available. Additional formulations for younger children will become available during the trial and dosing information will be updated. ADDITIONAL CRITERIA FOR ODYSSEY A: • Planning to start firstline ART ADDITIONAL CRITERIA FOR ODYSSEY B: Planning to start secondline ART defined as switch of at least 2 ART drugs due to treatment failure Treated with only one previous ART regimen At least one NRTI with predicted preserved activity available for a background regimen In settings where resistance tests are routinely available, at least one new active NRTI from tenofovir disoproxil fumarate, abacavir or zidovudine should have preserved activity based on cumulative results of resistance tests within 3 months In settings where resistance tests are not routinely available, children who are due to switch according to national guidelines should have at least one new NRTI predicted to be available from tenofovir disoproxil fumarate, abacavir or zidovudine Viral load &gt;1000 c/ml at screening visit History or presence of known allergy or some other contraindication to the study drugs or their components Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal, OR ALT ≥3x upper limit of normal and bilirubin ≥1.5x upper limit of normal Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Anticipated need for Hepatitis C virus (HCV) therapy during the study Pregnancy or breastfeeding Evidence of lack of susceptibility to integrase inhibitors or more than a 2week exposure to antiretrovirals of this class Contraindications to proposed available NRTI backbone</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>